HOOKIPA announces executive leadership change NEW YORK and VIENNA

HOOKIPA announces executive leadership change

YORK and VIENNA, September 13, 2023 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA'), a company developing a new

class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Katia Schlienger, M.D., Ph.D., is stepping

down from her position as Chief Medical Officer (CMO) to pursue new opportunities, effective September 30. Malte Peters, M.D., a current

member of the Board of Directors of HOOKIPA, will lead HOOKIPA's clinical activities ad interim as Senior Clinical Advisor until

a CMO search is complete. During this time, Dr. Peters will remain a member of the HOOKIPA Board of Directors.

Dr. Peters is a seasoned

executive with deep experience in bringing new therapies to patients. He retired from his role as Chief Research and Development Officer

at MorphoSys in 2022. Prior, Dr. Peters was Global Head of Clinical Development of the biopharmaceuticals business unit of Sandoz in Germany

and spent 12 years in leadership positions at Novartis Oncology. He was responsible for multiple development programs and clinical trials

at Novartis, contributing to the approval of 28 cancer therapies. He is board certified in internal medicine and earned his medical degree

from Freie Universit t in Berlin, with a postdoctoral fellowship in Toronto.

"We welcome Malte to HOOKIPA as we remain

laser focused on executing against our clinical priorities: to prepare for the randomized trial of HB-200 in combination with pembrolizumab,

to progress our HB-300 prostate cancer program, and to advance our partnered programs in our collaborations with Roche and Gilead,"

said Joern Aldag, Chief Executive Officer. "I would like to thank Katia for her many contributions to HOOKIPA, especially guiding

our clinical programs and bringing our lead HB-200 program to a successful proof-of concept in Phase 2. We wish her the very best in her

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage

biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed

to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA's replicating and non-replicating

technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.

HOOKIPA's pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive

cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for

KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

Forward Looking Statements

statements set forth in this press release constitute "forward-looking" statements within the meaning of the Private Securities

Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as "believes," "expects,"

"plans," "potential," "would" or similar expressions and the negative of those terms. Such forward-looking

statements involve substantial risks and uncertainties that could cause HOOKIPA's research and clinical development programs, future

results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such

risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA's

programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval

processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA's ability to successfully

establish, protect and defend its intellectual property, risks relating to business interruptions resulting from public health

crises, the impact of public health crises on the enrollment of patients and timing of clinical results, and other matters that could

affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking

statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in

these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA's quarterly

report on Form 10-Q for the quarter ended June 30, 2023, which is available on the SEC's website at www.sec.gov

and HOOKIPA's website at www.hookipapharma.com.

and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/),

SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with

our members and the public about our company, our services and other issues. It is possible that the information we post on social media

could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review

the information we post on the U.S. social media channels listed on our investor relations website.

For further information, please contact: